Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 117,237 | -110,938 | -34,625 | -30,344 | -3,268 |
| Depreciation Amortization | 19,840 | 6,485 | 216 | 125 | 0 |
| Income taxes - deferred | -15,573 | -2,460 | 76 | N/A | N/A |
| Accounts receivable | -4,504 | -7,959 | 0 | N/A | N/A |
| Accounts payable and accrued liabilities | 3,379 | 20,604 | 2,842 | 2,979 | 340 |
| Other Working Capital | -11,372 | 12,600 | 1,493 | 3,114 | 503 |
| Other Operating Activity | -110,396 | 35,818 | 12,409 | 21,389 | 1,639 |
| Operating Cash Flow | $-1,389 | $-45,850 | $-17,589 | $-2,737 | $-786 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -188,553 | -3,749 | -1,145 | N/A | N/A |
| PPE Investments | 148,389 | -663 | -117 | -25 | -3 |
| Net Acquisitions | -33,430 | -29,150 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | -400 | N/A | -373 | -10 |
| Sale Of Investment | N/A | 0 | 1,329 | N/A | N/A |
| Purchase Sale Intangibles | -7,008 | -3,301 | -5,433 | -1,168 | N/A |
| Other Investing Activity | -7,008 | -3,301 | -5,473 | -1,302 | 0 |
| Investing Cash Flow | $-80,602 | $-37,263 | $-5,406 | $-1,700 | $-13 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 930 | N/A |
| Debt Issued | N/A | 85,290 | N/A | N/A | N/A |
| Debt Repayment | N/A | -31,283 | N/A | N/A | N/A |
| Common Stock Issued | 160,780 | 48,398 | 30,937 | 3,476 | 763 |
| Common Stock Repurchased | N/A | -2,257 | -958 | N/A | N/A |
| Other Financing Activity | -59,178 | -4,828 | -998 | 32 | 46 |
| Financing Cash Flow | $101,602 | $95,320 | $28,981 | $4,438 | $809 |
| Exchange Rate Effect | -10 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 18,204 | 5,997 | 11 | 10 | N/A |
| End Cash Position | 37,805 | 18,204 | 5,997 | 11 | 10 |
| Net Cash Flow | $19,601 | $12,207 | $5,986 | $1 | $10 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,389 | -45,850 | -17,589 | -2,737 | -786 |
| Capital Expenditure | -22 | -663 | -117 | -25 | -3 |
| Free Cash Flow | -1,411 | -46,513 | -17,706 | -2,762 | -789 |